The GRK2158 lecture series is a major part of the GRK qualification program. During the first 2 semesters of the GRK a synchronization of the knowledge of the doctoral students in the field of preclinical drug discovery shall be attained. In the third and fourth semesters specialized lectures by internal and external lecturers from science, industry and public authorities will be held to get deeper insights in the individual stages of drug development.
The lectures will take place as online meetings at the given dates at 4:30 pm.
|06.04.2020||Microbial pathogenesis and antimicrobial chemotherapy||Klaus Pfeffer|
|20.04.2020||Microbial pathogenesis and antimicrobial chemotherapy||Rainer Kalscheuer|
|04.05.2020||Role of Apoptosis Signaling in Tumorigenesis and Therapy Resistance||Sebastian Wesselborg|
|18.05.2020||The Role of Autophagy in Cancer: Current Concepts and Therapeutic Implications||Björn Stork|
|25.05.2020||Immune response against microorganisms and tumors||Stefanie Scheu|
|08.06.2020||On the way to personalized tumor therapy||Rainer Haas|
|15.06.2020||Targeting the tumor microenvironment: Novel 3D co-culture organoids for pancreatic adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC)||Nicole Teusch|
|29.06.2020||How structural biology can help to identify resistance mechanisms||Sander Smits|
|13.07.2020||Virtual Screening||Holger Gohlke|
The lectures will start at 4:30 pm in lecture hall 6H (Building 26.41.).
|09.04.2018||Natural products and drug discovery||Peter Proksch|
|23.04.2018||Chemoenzymatic natural product synthesis||Jörg Pietruszka|
|14.05.2018||Diversity Oriented Synthesis of Bioactive Compounds by One-Pot Methodologies||Thomas J.J. Müller|
The lectures will take place in Building 25.22. Lecture Hall 5H starting at 4:30 pm.
|09.10.2017||How structural biology can help to identify resistance mechanisms||Sander Smits|
|23.10.2017||Virtual Screening||Holger Gohlke|
|13.11.2017||Drugs effects: Basics in Pharmacokinetics and dynamics||Gerhard Fritz|
|27.11.2017||From bench to bedside – Compound development on the example of Pitolisant, the first histamine H3 receptor antagonist on market||Holger Stark|
|11.12.2017||Cancer Chemoresistance||Matthias Kassack|
|15.01.2018||Development of Histone deacetylase inhibitors (metalloenzyme inhibitors)||Thomas Kurz|
[Translate to English:] The lectures will take place in Building 26.41. Lecture Hall 6H starting at 4:30 pm.
|24.04.2017||Microbial pathogenesis and antimicrobial chemotherapy||Klaus Pfeffer|
|15.05.2017||Microbial pathogenesis and antimicrobial chemotherapy||Rainer Kalscheuer|
|29.05.2017||Role of Apoptosis Signaling in Tumorigenesis and Therapy Resistance||Sebastian Wesselborg|
|19.06.2017||The Role of Autophagy in Cancer: Current Concepts and Therapeutic Implications||Björn Stork|
|03.07.2017||On the way to personalized tumor therapy||Rainer Haas|
|17.07.2017||Immune response against microorganisms and tumors||Stefanie Scheu|